Free Trial

3 Stocks That Could Rise on European Bank Interest Rate Cuts

3D Europe illustration covered in stock market tickers and up and down trade symbols for business and financial backgrounds, with the continent clipping path included in the file

Key Points

  • The U.S. is not the only country that has lowered interest rates; the U.K., Canada, and the European Union's central bank have also recently trimmed rates.
  • Several European companies stand to benefit from a lower interest rate environment.
  • Still, investors should watch out for signs that economies in the U.S. and elsewhere around the world may be cooling.
  • 5 stocks we like better than ASML.

U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated. Generally, a lower federal funds rate is often a boon for stocks, as businesses are able to more easily secure loans to facilitate growth and consumers may be more likely to increase spending habits.

The Federal Reserve is not the only central bank that has reduced interest rates heading into the final quarter of 2024. Similar institutions in Canada, the U.K., and other countries have begun to trim rates in recent months as well. Notably, the European Central Bank—the equivalent of the Federal Reserve for the European Union—cut some interest rates by 25 basis points in June and both deposit facility and refinancing rates in September as well. European stocks may stand to benefit from lower interest rates in the eurozone and, potentially, the U.S. as well.

IFNNY: Technological Breakthrough and Value Prospect

Infineon Technologies Today

Infineon Technologies AG stock logo
IFNNYIFNNY 90-day performance
Infineon Technologies
$32.71 -0.23 (-0.70%)
(As of 12/20/2024 05:55 PM ET)
52-Week Range
$30.06
$42.24
Dividend Yield
0.73%
P/E Ratio
31.15

Infineon Technologies AG OTCMKTS: IFNNY is a German fabricator of semiconductors and related products. With a market capitalization of under $45 billion, it is orders of magnitude smaller than major semiconductor rivals like NVIDIA Corp. NASDAQ: NVDA or Broadcom Inc. NASDAQ: AVGO. Smaller companies often stand to benefit in particular from lowered interest rates as they may be more likely than well-established firms to borrow money in order to finance expansion efforts.

Infineon is, indeed, in the midst of a major project to expand its offerings. The firm announced just days before the latest round of rate cuts that it would emphasize its gallium nitride (GaN) chips thanks to a technological advance that would reduce manufacturing costs. GaN chips are an alternative to popular silicon chips and are known for their light weight, efficiency, and resiliency to high temperatures, among other things.

Infineon's chips are often used in automotive applications. The automotive industry continues to be plagued by headwinds including supply chain issues and high prices, but Infineon nonetheless remains poised to grow as the automotive industry reverses course. Additionally, the chipmaker's P/E ratio of 16.3, significantly lower than many other semiconductor companies, gives it an attractive valuation in the meantime.

NVO: New Drugs in Progress

Novo Nordisk A/S Today

Novo Nordisk A/S stock logo
NVONVO 90-day performance
Novo Nordisk A/S
$85.00 -18.44 (-17.83%)
(As of 12/20/2024 05:45 PM ET)
52-Week Range
$81.50
$148.15
Dividend Yield
0.85%
P/E Ratio
27.51
Price Target
$150.40

Danish healthcare firm Novo Nordisk A/S NYSE: NVO trades on the New York Stock Exchange, but the international scope of its operations makes it susceptible to changes in interest rates globally. Novo Nordisk has captured headlines around the world with Ozempic, its popular medication used to address type 2 diabetes and obesity concerns.

Now, the firm has at least two more potential blockbuster drugs in various stages of development, and lowered interest rates may play a role in bringing these products to market. First, Wegovy is a weight loss and cardiovascular drug already approved by the FDA in the U.S. that has recently also been backed by the European Medicines Agency. To be sure, Wegovy is already highly successful, but expansion into Europe would help to solidify its blockbuster status.

Second, Novo Nordisk and biotech firm Korro Bio Inc. NASDAQ: KRRO have announced a collaboration seeking to develop two new genetic medicines to treat cardiometabolic disease. The scope of the project is massive, with Korro Bio set to receive up to $530 million to develop and commercialize the new medicines.

ASML: Large Semiconductor Firm Could Still Grow

ASML Today

ASML Holding stock logo
ASMLASML 90-day performance
ASML
$705.68 -4.58 (-0.64%)
(As of 12/20/2024 05:45 PM ET)
52-Week Range
$645.45
$1,110.09
Dividend Yield
0.79%
P/E Ratio
36.95
Price Target
$943.83

ASML Holdings N.V. NASDAQ: ASML is another semiconductor firm, though this one is based in the Netherlands. Despite its size relative to Infineon (it has a market cap of $327 billion), ASML has substantial growth potential.

Analysts have assigned it an average price target of $1,147.80, representing upside potential of 38.6%.

The firm is expected to post earnings growth of more than 63% in upcoming quarters. These factors help to make ASML an attractive prospect even as its P/E ratio is high at 40.8.

Future Rate Cuts Planned

The Federal Reserve has already signaled plans to continue to cut rates, and it is possible that the European Central Bank will follow suit. Depending on how these rate cuts are timed and how significant they are, they could help to facilitate a soft landing and continued economic growth or potentially pivot one or more economies into a recession. Thus, despite assurances that additional rate cuts are coming, investors may consider stocking up on shares of companies standing to benefit now.

→ The #1 Coin for November 2024 (From Crypto 101 Media) (Ad)

Should you invest $1,000 in ASML right now?

Before you consider ASML, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASML wasn't on the list.

While ASML currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Nathan Reiff
About The Author

Nathan Reiff

Contributing Author

Fundamental analysis, ETFs, Consumer Staples

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Infineon Technologies (IFNNY)
1.8566 of 5 stars
$32.71-0.7%0.73%31.15Strong BuyN/A
NVIDIA (NVDA)
4.929 of 5 stars
$134.70+3.1%0.03%53.01Moderate Buy$164.15
Broadcom (AVGO)
4.7381 of 5 stars
$220.79+1.1%1.07%191.82Moderate Buy$221.88
Novo Nordisk A/S (NVO)
3.7173 of 5 stars
$85.00-17.8%0.85%27.51Buy$150.40
Korro Bio (KRRO)
1.2579 of 5 stars
$43.67+1.3%N/AN/ABuy$142.17
ASML (ASML)
4.505 of 5 stars
$705.68-0.6%0.79%36.95Moderate Buy$943.83
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines